TransMedics Group, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $31.4M |
| Gross profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M |
| Operating income | $108.6M | $37.5M | -$28.7M | -$31.4M | -$39.4M |
| Operating expenses | $254.2M | $224.6M | $182.8M | $96.7M | $60.6M |
| Cost of revenue | $242.7M | $179.5M | $87.5M | $28.2M | $9.1M |
| Cash from operations | $192.8M | $48.8M | -$13.0M | -$45.8M | -$28.9M |
| Capital expenditure | $59.3M | $129.7M | $151.8M | $11.9M | $3.5M |
| Free cash flow | $133.6M | -$80.9M | -$164.9M | -$57.7M | -$32.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.1B | $804.1M | $706.0M | $277.1M | $134.9M |
| Total liabilities | $595.3M | $575.5M | $568.8M | $89.8M | $67.0M |
| Total debt | — | — | — | $60.0M | $35.0M |
Shares outstanding 34.6M · Free float 93.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.